Stocktoria
GERON CORP GERN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1996-07-31
GERON CORP financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $237,000 | $596,000 | $1.4M |
| SG&A expense | $159.3M | $145.7M | $69.1M | $43.6M | — |
| Operating income | -$68.6M | -$173.7M | -$193.9M | -$138.6M | -$114.0M |
| Interest expense | — | $18.5M | $8.3M | $6.9M | $3.7M |
| Income tax | $75,000 | $449,000 | $22,000 | — | — |
| Net income | -$83.5M | -$174.6M | -$184.1M | -$141.9M | -$116.1M |
| EPS (diluted) | $-0.13 | $-0.27 | $-0.32 | $-0.37 | $-0.35 |
| Operating cash flow | -$111.0M | -$218.6M | -$167.7M | -$127.4M | -$95.6M |
| Free cash flow | — | -$219.3M | -$168.6M | -$127.8M | -$95.8M |
| Cash & equivalents | $77.6M | $79.0M | $70.0M | $56.8M | $34.9M |
| Inventory | $116.6M | $38.7M | — | — | — |
| Total assets | $570.5M | $593.8M | $394.1M | $190.6M | $226.0M |
| Total liabilities | $344.7M | $313.5M | $146.1M | $110.6M | $99.6M |
| Shareholders' equity | $225.9M | $280.3M | $247.9M | $80.0M | $126.4M |
Source: SEC EDGAR filings · CIK 0000886744 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.